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Exclusion of the Nuclear Factor-kB3 (REL A) Gene as Candidate
for the Multiple Endocrine Neoplasia Type 1 (MEN 1) Gene
of MEN 1-associated tumors, the hereditary genetic
Multiple endocrine neoplasia type 1 (MEN 1) is defect had been assigned to chromosome 11q13.inherited as an autosomal dominant disorder, char-
Elimination of the wild-type allele at 11q13 loci inacterized by neoplasia and hyperplasia in speci®c
MEN 1 tumors suggests inactivation of a tumor sup-endocrine organs. The MEN 1 gene, which is most
pressor gene in this region as the causative mecha-probably a tumor suppressor gene, has been local-
nism in MEN 1 tumorigenesis (2).ized to a region of approximately 900 kb on chromo-
some 11q13. The nuclear factor-kB (NF-kB) is a tran- Loss of heterozygosity studies revealed a smallest
scription factor with pleiotropic expression, which region of overlapping deletions in MEN 1-associated
is involved in the regulation of expression of many tumors, ¯anked by the loci D11S427 and D11S97
cellular genes. The p50/p65 heterodimer is the most (3). Previous linkage analysis showed meiotic recom-
abundant form of NF-kB. The gene encoding the p65 binants in MEN 1 families for the locus D11S807
subunit (NF-kB3/REL A) was recently localized in (4). These studies place the MEN 1 locus betweenthe 900-kb MEN 1 region and was considered a good
the centromeric marker D11S427 and the telomericcandidate gene for MEN 1. The structure and nucle-
marker D11S807, a region of at most 900 kb (3).otide sequence of the NF-kB3 coding region in MEN
Nuclear factor-kB (NF-kB) represents a family of1 patients were compared with those of non-MEN 1
closely related homo- and heterodimers, whose mem-subjects, to determine the potential role of this gene
in MEN 1 tumorigenesis. Southern blot analysis bers belong to the Rel protein family of transcrip-
with constitutional DNA from probands of 14 inde- tional activators. This family includes p50 (NF-kB1),
pendent MEN 1 families and DNA from four MEN 1 p52 (NF-kB2), p65 (NF-kB3/RelA), Rel (c-Rel), and
tumor specimens did not reveal any structural ab- RelB (5). All these proteins are homologous to the
normality of the NF-kB3 gene. Direct sequencing of v-Rel oncoprotein (6). The NF-kB3 gene had been
cDNAs from two affected subjects from 2 different localized to chromosome 11q11±11q13, near theMEN 1 families, as well as nucleotide sequence anal-
ROM1 gene (7,8), centromeric to the 900-kb MEN 1ysis of exon/intron boundaries in these patients, did
region. However, recently it was shown that the NF-not reveal MEN 1-speci®c point mutations or other
kB3 gene maps within this MEN 1 region (9). Be-small structural aberrations in the NF-kB3 gene.
cause of its chromosomal location, the role of its en-These results make it very unlikely that the NF-kB3
gene is the gene responsible for the development of coded protein in transcription modulation, and its
MEN 1. q 1997 Academic Press ubiquitous expression pattern (as can be expected
for a tumor suppressor gene), the NF-kB3 gene was
considered a good candidate for being the MEN1
gene.Multiple endocrine neoplasia type 1 (MEN 1) is a
In this study, the structure and protein-encodingfamilial cancer syndrome with an autosomal domi-
sequence of the NF-kB3 gene in MEN 1 patientsnant pattern of inheritance. The disorder is charac-
were examined to detect possible MEN 1-speci®c ab-terized by the combined occurrence of hyperplasia
normalities. Southern blot analysis of constitutionalor tumors of the parathyroid glands, the pancreatic
DNA from affected subjects from 14 MEN 1 families,islets, and the anterior pituitary gland (1). Using
linkage analysis in MEN 1 families and allelotyping as well as DNA from four MEN 1-associated tumors,
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was performed to screen for large aberrations in the Germany) with [a-35S]dATP as the label. Sequencing
products were separated on 6% polyacrylamide gels,NF-kB3 gene. Additionally, we screened for point
mutations and other small aberrations, by sequenc- which were exposed to X-ray ®lms.
ing the entire protein-encoding region of NF-kB3
cDNA, synthesized on ®broblast RNA and tumor RESULTS AND DISCUSSION
RNA from affected subjects from 2 MEN 1-families.
For the Southern blot analysis, TaqI and EcoRI
restriction patterns of the NF-kB3 gene in blood andMATERIALS AND METHODS
tumor DNA from MEN 1 patients were compared to
DNA Isolation and Southern Blot Analysis the restriction patterns in DNA from blood from two
non-MEN 1 subjects. In the constitutional DNA, only
Blood was obtained from MEN 1 patients and non- the germ line mutation predisposing to MEN 1
affected family members from 14 unrelated families. might be detected, whereas the tumor DNA might
Tumor tissue was obtained from two glucagonomas, also reveal a somatic mutation, representing the sec-
one insulinoma, and one pituitary gland adenoma ond hit in Knudson's model for hereditary cancer
from four individual patients. DNA was isolated (14). We could not detect an aberrant restriction pat-
from blood and tumor samples according to Miller tern for any of the digests in either blood DNA or in
et al. (10). EcoRI- and TaqI-digested DNA (10 mg) tumor DNA (Fig. 2). Therefore, we decided to screen
was size-fractionated in 0.8% agarose gels and blot- for smaller MEN 1-speci®c changes, which would
ted onto Nylon/ membranes (Hybond, Amersham, result in the production of mutant mRNA, by se-
UK). Hybridizations were performed using a cosmid quencing the entire protein-encoding region of NF-
(cC21) containing the entire NF-kB3 gene, as well
kB3 mRNA. For this purpose, we performed RT/PCR
as 5* and 3 * ¯anking sequences (11). This clone was on RNA from a MEN 1 glucagonoma (thereby screen-
isolated from a grided ¯ow-sorted chromosome 11- ing for a germ line mutation as well as for somatic
speci®c cosmid library, kindly provided by Drs. Leh- mutations) and on RNA from a ®broblast cell line
rach and Zehetner (Max-Plank Institute, Berlin, from another MEN 1-patient, thereby screening for
Germany). Hybridizations were performed as de- the germ line mutation only.
scribed previously (12). The membranes were ex- Four partially overlapping DNA fragments were
posed overnight to a Phospho-imager screen (Molec- generated with the selected primers, as outlined in
ular Dynamics, Sunnyvale, CA), or to X-ray ®lms for Fig. 1. The entire coding region of NF-kB3 cDNA
1±7 days. was sequenced for both MEN 1 tissues. No MEN 1-
speci®c nucleotide sequence variants were detected,Nucleotide Sequence Analysis
when compared with NF-kB3 cDNA sequences
reported previously (15) (EMBL Accession Nos.The entire 1653-nucleotide coding region of NF-
kB3 mRNA was analyzed by sequencing overlapping Z22948-Z22954, inclusive). The intron/exon junc-
tions were sequenced using intron-speci®c primersDNA fragments obtained after RT/PCR (Fig. 1). RNA
was isolated from a frozen sample of glucagonoma after PCR of patients' DNAs. No mutation was found
in any case. Since we did not detect any commontissue and from a ®broblast cell culture, using RNA-
SR according to the manufacturer's instructions nucleotide sequence polymorphism in the RT/PCR
products, we were unable to prove that both alleles(Biogenesis, Bournemouth, UK). cDNA was synthe-
sized using Superscript reverse transcriptase (BRL, of the NF-kB3 gene were expressed and analyzed.
Theoretically, in the glucagonoma tissue analyzed,Breda, The Netherlands) and either a mixture of
oligo(dT)12±18 and random hexamers or NF-kB3-spe- one allele of the NF-kB3 gene might be missing/inac-
tivated due to a tumor-speci®c somatic mutationci®c oligonucleotides as primers (the nucleotide se-
quences and locations of the primers used for RT/ (second hit). In that case we have sequenced the
allele which should carry the germ line mutationPCR and nucleotide sequence analyses are available
on request). PCR was performed as described pre- (®rst hit). However, such a mutation was not de-
tected. In the ®broblast cell culture, both alleles ofviously (13). The PCR products were analyzed by
agarose gel electrophoresis. Speci®c products were the NF-kB3 gene should be present and expressed,
unless the germ line mutation in the family of thisisolated from ultra low melting point agarose gels
and used directly for nucleotide sequence analysis MEN 1 patient involves deletion/inactivation of this
gene. In contrast, for example, to Von Hippel-Lindauusing a pUC sequencing kit (Boehringer, Mannheim,
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FIG. 1. Schematic representation of the gene encoding NF-kB3. Exons are numbered 1±10; black boxes indicate protein-encoding
regions, shaded boxes indicate untranslated regions. Arrows indicate the location of oligonucleotide primers which were used to synthesize
four overlapping RT/PCR products on RNA (NF1F-NF2R, NF3F-NF4R, NF5F-NF6R, NF7F-NF8R). Bars at the bottom indicate PCR
products made on genomic DNA, for the analysis of intron/exon boundaries (detailed information on oligonucleotides available on request).
disease (VHL), where approximately 20% of the fam- all intron±exon junctions were sequenced on PCR
amplicons generated on DNA from these two af-ilies have a large germ line deletion in the VHL tu-
mor suppressor gene (16), germ line deletions in the fected subjects. In conclusion, these results make
it highly unlikely that the NF-kB3 gene is theMEN 1 locus have not yet been detected in MEN 1
families, making this possibility unlikely for the two MEN 1 gene.
patients we investigated.
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